Cancer Letters
Volume 291, Issue 1 , Pages 59-66 , 1 May 2010

Epithelial–mesenchymal transition in ovarian cancer

Received 3 August 2009 ,Revised 20 September 2009 ,Accepted 30 September 2009.

References 

  1. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion and metastasis: a role for epithelial–mesenchymal transition?. Cancer Res. 2005;65:5991–5995
  2. Geho DH, Bandle RW, Clair T, Liotta LA. Physiological mechanisms of tumor-cell invasion and migration. Physiology. 2005;20:194–200
  3. Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, et al. Focus on epithelial ovarian cancer. Cancer Cell. 2004;5:19–24
  4. Chen VW, Ruiz B, Killeen JL, Coté TR, Wu XC, Correa CN. Pathology and classification of ovarian tumors. Cancer. 2003;97:2631–2642
  5. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC. Ovarian surface epithelium: biology, endocrinology and pathology. Endocr. Rev. 2001;22:255–288
  6. Okamoto S, Okamoto A, Nikaido T, Saito M, Takao M, Yanaihara N, et al. Mesenchymal to epithelial transition in the human ovarian surface epithelium focusing on inclusion cysts. Oncol. Rep. 2009;21:1209–1214
  7. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer. 2003;3:362–374
  8. Naora H, Montell DJ. Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer. 2005;5:355–366
  9. Radisky DC. Epithelial–mesenchymal transition. J. Cell. Sci. 2005;118:4325–4326
  10. Thiery JP, Sleeman JP. Complex networks orchestrate epithelial–mesenchymal transitions. Nat. Rev. Mol. Cell. Biol. 2006;7:131–142
  11. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer. 2004;4:118–132
  12. Birchmeier W, Behrens J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta. 1994;1198:11–26
  13. Gamallo C, Palacios J, Suarez A, Pizarro A, Navarro P, Quintanilla M, et al. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am. J. Pathol. 1993;142:987–993
  14. von Burstin J, Eser S, Paul MC, Seidler B, Brandl M, Messer M, et al. E-cadherin regulates metastasis of pancreatic cancer in vivo and is suppressed by a SNAIL/HDAC1/HDAC2 repressor complex. Gastroenterology. 2009;137:361–371
  15. Kim MJ, Jang SJ, Yu E. Loss of E-cadherin and cytoplasmic–nuclear expression of β-catenin are the most useful immunoprofiles in the diagnosis of solid–pseudopapillary neoplasm of the pancreas. Hum. Pathol. 2008;39:251–258
  16. Kuwabara Y, Yamada T, Yamazaki K, Du WL, Banno K, Aoki D, et al. Establishment of an ovarian metastasis model and possible involvement of E-cadherin down-regulation in the metastasis. Cancer Sci. 2008;99:1933–1939
  17. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, et al. Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. Cancer Res. 2008;68:2329–2339
  18. Wu C, Cipollone J, Maines-Bandiera S, Tan C, Karsan A, Auersperg N, et al. The morphogenic function of E-cadherin-mediated adherens junctions in epithelial ovarian carcinoma formation and progression. Differentiation. 2008;76:193–205
  19. Sundfeldt K, Piontkewitz Y, Ivarsson K, Nilsson O, Hellberg P, Brännström M, et al. E-cadherin expression in human epithelial ovarian cancer and normal ovary. Int. J. Cancer. 1997;74:275–280
  20. Auersperg N, Pan J, Grove BD, Peterson T, Fisher J, Maines-Bandiera S, et al. E-cadherin induces mesenchymal-to-epithelial transition in human ovarian surface epithelium. Proc. Natl. Acad. Sci. USA. 1999;96:6249–6254
  21. Daraï E, Scoazec JY, Walker-Combrouze F, Mlika-Cabanne N, Feldmann G, Madelenat P, et al. Expression of cadherins in benign, borderline, and malignant ovarian epithelial tumors: a clinicopathologic study of 60 cases. Hum. Pathol. 1997;28:922–928
  22. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol. Int. 2006;62–70
  23. Veatch AL, Carson LF, Ramakrishnan S. Differential expression of the cell–cell adhesion molecule E-cadherin in ascites and solid human ovarian tumor cells. Int. J. Cancer. 1994;58:393–399
  24. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, et al. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell. Biol. 2000;2:84–89
  25. Bolós V, Peinado H, Pérez-Moreno MA, Fraga MF, Esteller M, Cano A. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell. Sci. 2003;116:499–511
  26. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol. Cell. 2001;7:1267–1278
  27. Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T, et al. Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am. J. Pathol. 2003;163:1437–1447
  28. Yoshida J, Horiuchi A, Kikuchi N, Hayashi A, Osada R, Ohira S, et al. Changes in the expression of E-cadherin repressors, Snail, Slug, SIP1 and Twist, in the development and progression of ovarian carcinoma: the important role of Snail in ovarian tumorigenesis and progression. Med. Mol. Morphol. 2009;42:82–91
  29. Roberts AB, Anzano MA, Lamb LC, Smith JM, Sporn MB. New class of transforming growth factors potentiated by epidermal growth factor: Isolation from non-neoplastic tissues. Proc. Natl. Acad. Sci. USA. 1981;78:5339–5343
  30. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat. Genet. 2001;29:117–129
  31. Massagué J. TGF-β signal transduction. Annu. Rev. Biochem. 1998;67:753–791
  32. Zhang YE. Non-Smad pathways in TGF-β signalling. Cell. Res. 2009;19:128–139
  33. Schmid P, Itin P, Rufli T. In situ analysis of transforming growth factors-β (TGF-β1, TGF-β2, TGF-β3) and TGF-β type II receptor expression in basal cell carcinomas. Br. J. Dermatol. 1996;134:1044–1051
  34. Schmid P, Itin P, Rufli T. In situ analysis of transforming growth factor-βs (TGF-β1, TGF-β2, TGF-β3), and TGF-β type II receptor expression in malignant melanoma. Carcinogenesis. 1995;16:1499–1503
  35. Tsushima H, Kawata S, Tamura S, Ito N, Shirai Y, Kiso S, et al. High levels of transforming growth factor β1 in patients with colorectal cancer: association with disease progression. Gastroenterology. 1996;110:375–382
  36. Higashi T, Sasagawa T, Inoue M, Oka R, Shuangying L, Saijoh K. Overexpression of latent transforming growth factor-β1 (TGF-β1) binding protein 1 (LTBP-1) in association with TGF-β1 in ovarian carcinoma. Jpn. J. Cancer Res. 2001;92:506–515
  37. Inan S, Vatansever S, Celik-Ozenci C, Sanci M, Dicle N, Demir R. Immunolocalizations of VEGF, its receptors flt-1, KDR and TGF-β’s in epithelial ovarian tumors. Histol. Histopathol. 2006;21:1055–1064
  38. Marth C, Lang T, Koza A, Mayer I, Daxenbichler G. Transforming growth factor-β and ovarian carcinoma cells: regulation of proliferation and surface antigen expression. Cancer Lett. 1990;51:221–225
  39. Zhou L, Leung BS. Growth regulation of ovarian cancer cells by epidermal growth factor and transforming growth factors α and β1. Biochim. Biophys. Acta. 1992;1180:130–136
  40. Jozan S, Guerrin M, Mazars P, Dutaur M, Monsarrat B, Cheutin F, et al. Transforming growth factor β1 (TGF-β1) inhibits growth of a human ovarian carcinoma cell line (OVCCR1) and is expressed in human ovarian tumors. Int. J. Cancer. 1992;52:766–770
  41. Yamada SD, Baldwin RL, Karlan BY. Ovarian carcinoma cell cultures are resistant to TGF-β1-mediated growth inhibition despite expression of functional receptors. Gynecol. Oncol. 1999;75:72–77
  42. Dunfield LD, Dwyer EJ, Nachtigal MW. TGF β-induced Smad signaling remains intact in primary human ovarian cancer cells. Endocrinology. 2002;143:1174–1181
  43. Baldwin RL, Tran H, Karlan BY. Loss of c-myc repression coincides with ovarian cancer resistance to transforming growth factor β growth arrest independent of transforming growth factor β/Smad signalling. Cancer Res. 2003;63:1413–1419
  44. Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat. Cell. Biol. 2001;3:392–399
  45. Sunde JS, Donninger H, Wu K, Johnson ME, Pestell RG, Rose GS, et al. Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-β signaling in ovarian cancer. Cancer Res. 2006;66:8404–8412
  46. Fischer-Colbrie J, Witt A, Heinzl H, Speiser P, Czerwenka K, Sevelda P, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Anticancer Res. 1997;17:613–619
  47. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell. Biol. 1994;127:2021–2036
  48. Kitagawa K, Murata A, Matsuura N, Tohya K, Takaichi S, Monden M, et al. Epithelial–mesenchymal transformation of a newly established cell line from ovarian adenosarcoma by transforming growth factor-β1. Int. J. Cancer. 1996;66:91–97
  49. Piek E, Moustakas A, Kurisaki A, Heldin CH, ten Dijke P. TGF-(β) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J. Cell. Sci. 1999;112:4557–4568
  50. Keshamouni VG, Michailidis G, Grasso CS, Anthwal S, Strahler JR, Walker A, et al. Differential protein expression profiling by iTRAQ–2DLC–MS/MS of lung cancer cells undergoing epithelial–mesenchymal transition reveals a migratory/invasive phenotype. J. Proteome Res. 2006;5:1143–1154
  51. Keshamouni VG, Jagtap P, Michailidis G, Strahler JR, Kuick R, Reka AK, et al. Temporal quantitative proteomics by iTRAQ 2D-LC–MS/MS and corresponding mRNA expression analysis identify post-transcriptional modulation of actin-cytoskeleton regulators during TGF-β-Induced epithelial–mesenchymal transition. J. Proteome Res. 2009;8:35–47
  52. Cui W, Fowlis DJ, Bryson S, Duffie E, Ireland H, Balmain A, et al. TGF-β1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell. 1996;86:531–542
  53. Bartlett JM, Langdon SP, Simpson BJ, Stewart M, Katsaros D, Sismondi P, et al. The prognostic value of epidermal growth factor receptor mRNA expression in primary ovarian cancer. Br. J. Cancer. 1996;73:301–316
  54. Hegymegi-Barakonyi B, Eros D, Szántai-Kis C, Breza N, Bánhegyi P, Szabó GV, et al. Tyrosine kinase inhibitors – small molecular weight compounds inhibiting EGFR. Curr. Opin. Mol. Ther. 2009;11:308–321
  55. Rivera F, Vega-Villegas ME, López-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs. 2008;19:99–113
  56. Yingling JM, Blanchard KL, Sawyer JS. Development of TGF-β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 2004;3:1011–1022
  57. Ahmed N, Maines-Bandiera S, Quinn MA, Unger WG, Dedhar S, Auersperg N. Molecular pathways regulating EGF-induced epithelio-mesenchymal transition in human ovarian surface epithelium. Am. J. Physiol. Cell. Physiol. 2006;290:1532–1542
  58. Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int. J. Cancer. 2007;120:2426–2434
  59. Colomiere M, Findlay J, Ackland L, Ahmed N. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of α6 and β1 integrin. Int. J. Biochem. Cell. Biol. 2009;41:1034–1045
  60. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, et al. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial–mesenchymal transition in ovarian carcinomas. Br. J. Cancer. 2009;100:134–144
  61. Sowter HM, Corps AN, Smith SK. Hepatocyte growth factor (HGF) in ovarian epithelial tumour fluids stimulates the migration of ovarian carcinoma cells. Int. J. Cancer. 1999;83:476–480
  62. Di Renzo MF, Olivero M, Katsaros D, Crepaldi T, Gaglia P, Zola P, et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int. J. Cancer. 1994;58:658–662
  63. Wong AS, Roskelley CD, Pelech S, Miller D, Leung PC, Auersperg N. Progressive changes in Met-dependent signaling in a human ovarian surface epithelial model of malignant transformation. Exp. Cell. Res. 2004;299:248–256
  64. Zhou HY, Wong AS. Activation of p70S6K induces expression of matrix metalloproteinase 9 associated with hepatocyte growth factor-mediated invasion in human ovarian cancer cells. Endocrinology. 2006;147:2557–2566
  65. Pon YL, Zhou HY, Cheung AN, Ngan HY, Wong AS. p70 S6 kinase promotes epithelial to mesenchymal transition through snail induction in ovarian cancer cells. Cancer Res. 2008;68:6524–6532
  66. Le XF, Hittelman WN, Liu J, McWatters A, Li C, Mills GB, et al. Paclitaxel induces inactivation of p70 S6 kinase and phosphorylation of Thr421 and Ser424 via multiple signaling pathways in mitosis. Oncogene. 2003;22:484–497
  67. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332:411–415
  68. Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br. J. Cancer. 2003;88:163–166
  69. Bagnato A, Salani D, Di Castro V, Wu-Wong JR, Tecce R, Nicotra MR, et al. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 1999;59:720–727
  70. Salani D, Di Castro V, Nicotra MR, Rosanò L, Tecce R, Venuti A, et al. Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathos. 2000;157:1537–1547
  71. Spinella F, Rosanò L, Elia G, Di Castro V, Natali PG, Bagnato A. Endothelin-1 stimulates cyclooxygenase-2 expression in ovarian cancer cells through multiple signaling pathways: evidence for involvement of transactivation of the epidermal growth factor receptor. J. Cardiovasc. Pharmacol. 2004;44:140–143
  72. Rosanò L, Spinella F, Di Castro V, Nicotra MR, Dedhar S, de Herreros AG, et al. Endothelin-1 promotes epithelial–mesenchymal transition in human ovarian cancer cells. Cancer Res. 2005;65:11649–11657
  73. Erickson GF, Shimasaki S. The spatiotemporal expression pattern of the bone morphogenetic protein family in rat ovary cell types during the estrous cycle. Reprod. Biol. Endocrinol. 2003;5:9
  74. Shepherd TG, Nachtigal MW. Identification of a putative autocrine bone morphogenetic protein-signaling pathway in human ovarian surface epithelium and ovarian cancer cells. Endocrinology. 2003;144:3306–3314
  75. Schindl M, Schoppmann SF, Ströbel T, Heinzl H, Leisser C, Horvat R, et al. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors. Clin. Cancer Res. 2003;9:779–785
  76. Thériault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis. 2007;28:1153–1162
  77. Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. 2005;65:5996–6000
  78. Zavadil J, Haley J, Kalluri R, Muthuswamy SK, Thompson E. Epithelial–mesenchymal transition. Cancer Res. 2008;68:9574–9577
  79. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, et al. The epithelial–mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–715
  80. Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S, Puisieux A. Generation of breast cancer stem cells through epithelial–mesenchymal transition. PLoS One. 2008;3:2888
  81. Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69:2887–2895
  82. Kurrey NK, Jalgaonkar SP, Joglekar AV, Ghanate AD, Chaskar PD, Doiphode RY, et al. Snail and Slug mediate radio- and chemo-resistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009;27:2059–2068
  83. Shih IeM, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am. J. Pathol. 2004;164:1511–1518

PII: S0304-3835(09)00616-8

doi: 10.1016/j.canlet.2009.09.017

Cancer Letters
Volume 291, Issue 1 , Pages 59-66 , 1 May 2010

Article Tools

* Image Usage & Resolution